Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
VistaGen Therapeutics (VTGN) announced promising data from its second preclinical study of AV-101 combined with probenecid, which may enhance the treatment of central nervous system (CNS) disorders. The study showed that the combination significantly raised brain levels of AV-101's active metabolite, 7-Cl-KYN, improving its therapeutic potential. AV-101, with an excellent safety profile and no significant side effects, could offer a new treatment option for anxiety and depression. The findings could lead to further clinical development under FDA's Fast Track designation for both major depressive disorder and neuropathic pain.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical firm focused on CNS disorders, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. CEO Shawn Singh will speak on September 3 at 11 a.m. EDT. Investors can watch the live webcast by registering online. VistaGen's pipeline includes three drug candidates targeting anxiety and depression, all showing promising safety profiles. The presentation aims to highlight the company's innovative approach to treating CNS disorders and its position within the micro-cap market.
VistaGen Therapeutics (Nasdaq: VTGN) reported its fiscal 2021 Q1 results, highlighting key advancements in its drug development pipeline. The Company reached an agreement with the FDA on PH94B's Phase 3 study for social anxiety disorder, with enrollment for 182 adults planned. Financially, VistaGen secured a $5 million non-dilutive license payment and completed a public offering, raising approximately $14.29 million. Notably, net loss decreased to $3.5 million, while R&D expenses dropped from $4.3 million to $1.7 million compared to the previous year.
VistaGen Therapeutics (Nasdaq: VTGN) announced that underwriters of its public offering exercised their over-allotment option, bringing additional gross proceeds of approximately $1.79 million. Overall, the offering totaled $14.29 million with 17,868,250 shares issued. The funds will support the development of CNS pipeline programs, general research, and working capital. Maxim Group LLC managed the offering, which was conducted under an effective shelf registration statement with the SEC.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) has closed an underwritten public offering of 15,625,000 shares at $0.80 per share, generating $12.5 million in gross proceeds. The proceeds will support the development of CNS pipeline programs, R&D, and general corporate purposes. An option for underwriters to purchase up to an additional 2,343,750 shares within 45 days is also granted. The offering was conducted under an effective shelf registration statement.
VistaGen Therapeutics (NASDAQ: VTGN) received a $5 million non-dilutive upfront license payment from EverInsight Therapeutics for the development of PH94B, a nasal spray targeting anxiety-related disorders. This collaboration focuses on commercializing PH94B in key Asian markets, including Greater China and Southeast Asia.
VistaGen is eligible for milestone payments and royalties on future sales. The FDA has granted Fast Track designation for PH94B's Phase 3 development as a treatment for social anxiety disorder (SAD), marking it as a potential breakthrough in non-addictive anxiety treatment.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) announced the pricing of a public offering of 15,625,000 shares at $0.80 per share, aiming to raise gross proceeds of approximately $12.5 million. The underwriter has a 45-day option to purchase an additional 2,343,750 shares. The funds will support the development of its central nervous system (CNS) pipeline programs as well as general research and development. This offering is part of an effective shelf registration statement filed with the SEC.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has announced an underwritten public offering of common stock, subject to market conditions. The company aims to utilize the proceeds for the continued development of its central nervous system (CNS) pipeline, general research, working capital, and corporate purposes. Maxim Group LLC serves as the sole book-running manager for the offering. This offering is made under an effective shelf registration statement, and a preliminary prospectus supplement will be filed with the SEC.
VistaGen Therapeutics (VTGN) reported its financial results for the fiscal year ending March 31, 2020. The company experienced a decrease in net loss to $22 million from $25.7 million the previous year, primarily due to lower research and development expenses. VistaGen's cash position stood at $1.4 million, with subsequent proceeds of $3 million after fiscal year-end. The strategic collaboration with EverInsight aims to develop PH94B, a nasal spray for anxiety disorders, with potential payments up to $177 million, enhancing the company's pipeline targeting mental health care.
VistaGen Therapeutics (NASDAQ: VTGN) has entered a strategic licensing agreement with EverInsight Therapeutics for the development and commercialization of PH94B, a novel neurosteroid for anxiety disorders, in Greater China, South Korea, and Southeast Asia. VistaGen will receive a $5 million upfront payment and potential milestone payments of up to $172 million. The collaboration aims to advance Phase 3 clinical development for PH94B, which has Fast Track designation from the FDA for social anxiety disorder. VistaGen retains rights outside this territory.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
